USANA Health Sciences, Inc. USNA R2KR3K
Company Overview
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $925.26M (+8.3% YoY); net profit $10.76M.
- Trailing 12 Months Year-on-year growth — revenue -5.3%, earnings -74.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR -6.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.80% |
| 1 Year: | -5.30% |
Compounded Profit Growth
| 5 Years: | -6.86% |
| 1 Year: | -74.40% |
Stock Price Performance
| 1 Year: | -53.61% |
| 6 Months: | -18.59% |
| 3 Months: | -19.50% |
| 1 Month: | -2.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.78 · Neutral
P/E of 29.04 is above the sector median of 18.74 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -6.9% CAGR over 5 years.
- Trading 55.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | USNA USANA Health Sciences, Inc. R2KR3K | 14.52 | 29.04 | $268.08M | 0.00% | 6.09% | -5.06% | 4.80% | -6.86% |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 37.73 | $852.63B | 0.88% | 16.83% | 24.13% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 915.74 | 46.16 | $406.11B | 0.62% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.07 | 26.45 | $378.93B | 2.44% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 146.44 | 22.32 | $341.00B | 2.96% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 182.53 | 25.07 | $284.49B | 3.13% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 137.63 | 18.04 | $188.00B | 4.28% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 80.35 | 17.32 | $140.40B | 1.61% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | MO Altria Group, Inc. SPXR3K | 68.88 | 14.50 | $115.01B | 6.26% | 38.27% | - | 1.24% | -1.89% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2015 | Apr 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 266.62M | 258.99M | 298.51M | 307.98M | 336.84M | 274.35M | 272.87M | 264.47M | 233.30M | 248.36M | 238.20M | 213.37M | 227.80M | 212.87M | 200.22M | 249.54M | 235.85M | 213.67M | 250.22M |
| Gross Profit | 190.35M | 181.01M | 193.16M | 192.24M | 192.40M | 197.53M | 212.54M | 209.24M | 206.58M | 212.67M | 213.16M | 214.63M | 227.40M | 242.62M | 251.47M | 244.89M | 249.56M | 227.09M | 209.52M | 212.78M | 224.01M | 220.56M | 211.32M | 242.16M | 250.32M | 279.82M | 223.64M | 221.48M | 214.96M | 186.74M | 199.84M | 194.88M | 170.84M | 184.73M | 172.54M | 160.96M | 197.09M | 185.66M | 164.85M | 190.78M |
| Operating Income | - | 29.79M | 38.77M | 37.97M | - | 33.50M | 37.45M | 35.83M | - | 32.89M | 32.37M | 31.36M | - | 43.13M | 51.14M | 45.51M | - | 35.00M | 31.16M | 35.46M | - | 39.01M | 39.59M | 45.35M | 44.20M | 53.72M | 40.77M | 33.07M | 29.37M | 22.63M | 26.84M | 24.40M | 17.61M | 24.67M | 17.84M | 15.60M | 15.67M | 16.72M | 1.22M | 13.87M |
| Net Income | 21.30M | 19.68M | 25.42M | 25.61M | 23.97M | 22.30M | 25.76M | 30.10M | 21.88M | 21.36M | 23.26M | 23.77M | -5.85M | 28.95M | 33.91M | 31.04M | 32.33M | 24.17M | 21.38M | 24.22M | 30.75M | 26.55M | 27.98M | 30.51M | 30.62M | 38.23M | 27.33M | 22.47M | 19.16M | 14.93M | 18.38M | 17.29M | 11.35M | 16.54M | 10.43M | 10.61M | 9.40M | 9.65M | -6.52M | 7.51M |
| Diluted EPS | 1.65 | 0.75 | 0.96 | 0.96 | 0.92 | 0.89 | 1.03 | 1.20 | 0.87 | 0.86 | 0.93 | 0.97 | -0.24 | 1.19 | 1.36 | 1.24 | 1.32 | 1.01 | 0.91 | 1.09 | 1.41 | 1.23 | 1.32 | 1.44 | 1.45 | 1.87 | 1.36 | 1.15 | 1.00 | 0.78 | 0.95 | 0.89 | 0.59 | 0.86 | 0.54 | 0.56 | 0.49 | 0.52 | -0.36 | 0.41 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 436.94M | 517.64M | 581.94M | 648.73M | 718.17M | 790.47M | 918.50M | 1.01B | 1.05B | 1.19B | 1.06B | 1.13B | 1.19B | 998.60M | 921.01M | 854.50M | 925.26M |
| Gross Profit | 347.14M | 422.16M | 480.25M | 532.92M | 590.74M | 649.68M | 758.82M | 825.89M | 867.86M | 988.54M | 873.40M | 925.53M | 968.57M | 804.71M | 744.32M | 693.29M | 724.40M |
| Operating Income | 50.79M | 68.22M | 77.26M | 98.18M | 116.71M | 116.10M | 141.66M | 138.62M | 132.50M | 188.35M | 146.19M | 176.49M | 170.19M | 107.61M | 93.07M | 66.32M | 37.43M |
| Net Income | 33.56M | 45.65M | 50.75M | 66.43M | 79.02M | 76.64M | 94.67M | 100.04M | 62.53M | 126.22M | 100.53M | 124.66M | 116.50M | 69.35M | 63.79M | 42.03M | 10.76M |
| Diluted EPS | 2.17 | 2.86 | 3.26 | 4.45 | 5.56 | 2.80 | 3.59 | 3.99 | 2.53 | 5.12 | 4.41 | 5.86 | 5.73 | 3.59 | 3.30 | 2.19 | 0.58 |
| R&D Expense | - | 3.84M | 4.07M | 4.66M | 5.08M | 5.13M | 6.42M | 8.84M | 8.95M | 10.24M | 10.26M | 10.63M | 11.11M | 11.56M | 11.45M | 11.57M | 10.69M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2009 | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 216.64M | 244.50M | 267.36M | 368.47M | 350.58M | 423.24M | 470.64M | 519.27M | 554.46M | 516.93M | 640.89M | 577.74M | 596.55M | 632.76M | 748.19M | 742.91M |
| Total Equity | 31.84M | 74.37M | 146.80M | 173.91M | 185.57M | 260.52M | 230.16M | 280.85M | 325.29M | 363.21M | 391.15M | 351.71M | 441.65M | 395.12M | 434.47M | 497.20M | 532.11M | 533.10M |
| Cash & Equivalents | 13.28M | 13.66M | 50.35M | 50.35M | 70.84M | 137.34M | 111.13M | 143.21M | 175.77M | 247.13M | 214.33M | 234.83M | 311.92M | 239.83M | 288.42M | 330.42M | 181.77M | 158.38M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 135.56M | 161.86M | 156.64M |
| Current Liabilities | - | - | 59.03M | 59.70M | 70.84M | 95.87M | 108.70M | 131.41M | 138.49M | 141.18M | 148.69M | 136.10M | 168.07M | 160.79M | 143.83M | 118.84M | 139.62M | 128.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 32.47M | 66.11M | 70.11M | 92.81M | 98.89M | 105.19M | 111.47M | 136.89M | 123.77M | 152.12M | 126.73M | 160.40M | - | 121.23M | 103.90M | 70.64M | 60.99M | 22.35M | 22.35M |
| Investing Cash Flow | -3.20M | -46.85M | -10.61M | -8.28M | -21.59M | -16.27M | -25.12M | -31.88M | -12.90M | -69.00M | 47.49M | -33.96M | - | -14.19M | -12.37M | -11.97M | -213.09M | -10.12M | -10.12M |
| Financing Cash Flow | -29.50M | -9.58M | -33.37M | -64.54M | -10.16M | -113.02M | -49.16M | -64.86M | -50.32M | -105.28M | -152.05M | -59.44M | - | -181.41M | -30.09M | -14.24M | 9.55M | -40.60M | -40.60M |
| Capital Expenditure | -4.13M | -4.19M | -10.64M | -8.43M | -8.05M | -20.42M | -23.73M | -32.70M | -13.22M | -11.43M | -16.57M | -15.09M | - | -12.76M | -10.40M | -14.49M | -10.07M | -13.82M | -13.82M |
| Free Cash Flow | 28.34M | 61.92M | 59.47M | 84.37M | 90.84M | 84.76M | 87.74M | 104.19M | 110.55M | 140.69M | 110.16M | 145.31M | - | 108.46M | 93.50M | 56.15M | 50.92M | 8.53M | 8.53M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.44M | 44.43M | -142.54M | -28.38M | - |
| Share Buybacks | 1.65M | 17.03M | 33.46M | 68.29M | 18.09M | 138.82M | 61.18M | 64.61M | 50.00M | 105.38M | 150.00M | 57.03M | - | 177.84M | 25.38M | 11.60M | 9.44M | - | 27.51M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2010 | Jan 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 79.4% | 81.6% | 82.5% | 82.1% | 82.3% | 82.2% | 82.6% | 82.1% | 82.9% | 83.1% | 82.3% | 81.6% | 81.6% | 80.6% | 80.8% | 81.1% | 78.3% |
| Operating Margin % | 11.6% | 13.2% | 13.3% | 15.1% | 16.3% | 14.7% | 15.4% | 13.8% | 12.7% | 15.8% | 13.8% | 15.6% | 14.3% | 10.8% | 10.1% | 7.8% | 4.0% |
| Net Margin % | 7.7% | 8.8% | 8.7% | 10.2% | 11.0% | 9.7% | 10.3% | 9.9% | 6.0% | 10.6% | 9.5% | 11.0% | 9.8% | 6.9% | 6.9% | 4.9% | 1.2% |
| ROE % | 45.1% | 31.1% | 29.2% | 35.8% | 30.3% | 33.3% | 33.7% | 30.8% | 17.2% | 32.3% | 28.6% | 28.2% | 29.5% | 16.0% | 12.8% | 7.9% | 2.0% |
| ROCE % | - | 43.3% | 41.8% | 50.0% | 42.8% | 48.0% | 48.5% | 41.7% | 35.0% | 46.4% | 38.4% | 37.3% | 40.8% | 23.8% | 18.1% | 10.9% | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.41% | 1.55M | $21.82M |
| 2 | Pzena Investment Management LLC | 6.52% | 1.21M | $16.93M |
| 3 | Renaissance Technologies, LLC | 5.19% | 958.52K | $13.46M |
| 4 | Dimensional Fund Advisors LP | 4.53% | 837.43K | $11.76M |
| 5 | Nantahala Capital Management, LLC | 4.38% | 810.07K | $11.37M |
| 6 | Vanguard Capital Management LLC | 2.64% | 487.37K | $6.84M |
| 7 | Creative Planning | 2.26% | 417.97K | $5.87M |
| 8 | AQR Capital Management, LLC | 2.21% | 408.09K | $5.73M |
| 9 | Vanguard Portfolio Management LLC | 1.97% | 363.38K | $5.10M |
| 10 | Geode Capital Management, LLC | 1.53% | 283.17K | $3.98M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for USNA
Why USANA (USNA) Stock Is Nosediving - StockStory
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPWmcyNDdTOU9Eak40clNPRHlQdTBBWXBqQVVYTFNXVVR1eklhZVRvUnhqd09fSWI4cmp1Y29yVE5uY2tJd2xLOVFoS3pNeVd1ZklOc2hyZFJoajVRYl85SUhGZ0xyajI4eGprTWk3ZEV3NVFqMDE5ZVJmbGYtX0MwLUxRQlpGUHY5WjNOVU…
A clear soda has 15 grams of protein, 5 grams of fiber and 0 grams of sugar - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNOW9LZk1aalpVSU4zMG50TGN4S2JQV2p3U0VrNzBxSlNMUXZNQUVtWFJ3MXVvSGh1ZGhuNkwxTVFxeU5FTzhXR1dFNmZXbmpoUmlka2dMamoya2JkVEk1aDdWM0Z4Y3pzYXVKRDVqTnRNTHVqZWdNbUVoenotLWxzWHBQdG5fU19LejUya1…
Should Value Investors Buy USANA Health Sciences (USNA) Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxObHByN2NxRXN1UzhjT0NWVDRIN196dHY2Wjgxc19JdFVvYnhRc0YtTGJSWEJpS0VMbkhQY1lUdHRmSVBRcVUxYXBRTlM0WGQ4M2Rnemhhcm8wcVRsbl80RmVTQUh2Rjdxc2EzTFRuS3ctYmhKZm9mWUIzdEl1Mk5QYWczYkZnWldqdXRqYn…
Empowered Funds LLC Invests $1.50 Million in USANA Health Sciences, Inc. $USNA - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNSFBocFZHMzMwLWNlMVNWdklOQmRDbEltemNNb25mclpLeVpDdGtiQS1oMmM0b2h1Q3ZHNHlVZjVjMHFPWWtPMmtNeGt0NDQxOEtCWEpFbXJ1WF9vOGpTNTFaajY4bzBXcFJ6akJOLXo4Mjl3LV9acW12VURhakdnbDdNdGktOGlJZW1iUl…
3 Reasons to Sell USNA and 1 Stock to Buy Instead - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQS25xWTdyX2Z4MEtqblR5Vm5ZVzRHWm0xaEQ3Q3RneUYxTUlhNFZ3M0MtTzdzeGpGUlZfTnhwZzZxS2ZRc0dvOXNPXzVRbmtBWkpOYW5LbThpQmhDSFBEOGRzY0otLU9EQ1NIS2FNTC1mcHgyanJ2eS11a2U1ZEwxQjkxN3MwVTYxQmNQNn…
3 Reasons to Sell USNA and 1 Stock to Buy Instead - Barchart.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPUDRZekhNMUNqZWZGX01zX2FTaTU4dzMtc2RDM3pEVk1lQ1U5VGFHWXRCbWRyN01jaTJSZy03aUFfUzYxSHBPeHVfb3NWZnNvVTZoZ194NW1oWFB2clgzd01CbVk4Zk5LYV8ydTRxdmhScE44ejBqQ1BLRWNCcUZIWWdPbWhRNmdURTlXT2…
USNA — Frequently Asked Questions
What is the current share price of USANA Health Sciences, Inc. (USNA)?
As of 2026-09-07 16:24 PDT, USANA Health Sciences, Inc. (USNA) trades at $14.52 on NYSE. Its 52-week range is $12.86 to $32.24.
What is the market capitalisation of USNA?
USANA Health Sciences, Inc. (USNA) has a market capitalisation of $268.08M on NYSE.
What is the P/E ratio of USNA?
USNA trades at a trailing price-to-earnings (P/E) ratio of 29.04. The industry average P/E is 18.74. Its price-to-book (P/B) ratio is 0.54.
What is the return on equity (ROE) of USNA?
USNA has a return on equity (ROE) of -5.06%. Its return on capital employed (ROCE) is 6.09%.
Is USNA a good stock to buy?
This page provides a data-driven analysis of USANA Health Sciences, Inc. (USNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.